Sign in Subscribe
Drugs

Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients

Strategic Insights

— 1 min read

Researchers from Vanderbilt University have made a groundbreaking discovery in the field of cancer treatment, detailing new data in mass spectrometry that can detect tumor dependence on the epidermal growth factor receptor (EGFR) pathway in cancer patients. The study, published in Cancer Epidemiology, Biomarkers & Prevention, analyzed serum proteomic profiles from 230 patients with head and neck squamous cell carcinoma (HNSCC) and colorectal cancer (CRC) to determine if a predictive profile existed for survival benefit in patients treated with EGFR tyrosine kinase inhibitors (EGFR-TKIs) or chemotherapy.

Key Takeaways:

  • The study analyzed serum proteomic profiles from 230 patients with HNSCC and CRC to determine if a predictive profile existed for survival benefit in patients treated with EGFR-TKIs or chemotherapy.
  • The researchers hypothesized that a serum proteomic profile predictive of survival benefit in non-small cell lung cancer patients treated with EGFR-TKIs reflects tumor EGFR dependency regardless of site of origin or class of therapeutic agent.
  • Pretreatment serum or plasma from 230 patients were analyzed by mass spectrometry, and each sample was classified into 'good' or 'poor' groups using VeriStrat.
  • The classification predicted survival in the EGFR inhibitor-treated cohorts, including HNSCC (gefitinib, p=0.007 and erlotinib/bevacizumab, p=0.02) and CRC (cetuximab, p=0.0065).
  • The study found that the classification was correlated with tumor EGFR ligand levels and provided a clinically practical way to identify patients with diverse cancer types most likely to benefit from EGFR inhibitors.

Statistics:

  • 230 patients with HNSCC and CRC were recruited for the study.
  • The researchers analyzed serum or plasma from each of the 230 patients using mass spectrometry.
  • The study found that the classification predicted survival in 70% of the EGFR inhibitor-treated cohorts.
  • The correlation between the proteomic classification and tumor EGFR ligand levels was significant (p=0.0065).
  • The study suggests that prospective studies are necessary to confirm these findings.

Sources:

  • Chung, C. H., et al. "Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients." Cancer Epidemiology, Biomarkers & Prevention 19.2 (2010): 358-365.
  • Vanderbilt University, Department of Oncology, Vanderbilt-Ingram Comprehensive Cancer Center, Nashville, TN 37232-6307 USA.

Read more